

Brief description of the activities during the applicable regulatory review period.

IND Activities

Date of Contact	Summary of Contact
3-Feb-1993	FDA Acknowledged receipt of IND submission (SN000, dated January 27, 1993).
16-Feb-1993	Response to request for information.
15-Mar-1993	Protocol amendment
2-Jul-1993	Request for meeting
10-Aug-1993	Comments from Agency and request for teleconference.
17-Aug-1993	Response to request for information.
24-Sep-1993	Minutes from clinical development plan meeting held on September 3, 1993.
4-Nov-1993	Revised meeting minutes from September 3, 1993 clinical development plan meeting reflecting the Agency's comments.
10-Dec-1993	Information amendment
14-Jan-1994	Protocol amendment
8-Apr-1994	Comments from FDA regarding IND amendment dated December 10, 1993
27-Apr-1994	IND annual report
20-May-1994	New protocol
18-Jul-1994	Protocol amendment
18-Oct-1994	Protocol amendment
4-Nov-1994	Letter of Authorization regarding IND 41,574.
6-Dec-1994	Regarding obtaining written guideline on interactive IND process and inquiring how much time new MRO requests to review draft Phase III protocols.
20-Jan-1995	Information amendment
3-Mar-1995	Request for designation; recommendation for primary review authority be given to Pilot Drug Division under jurisdiction of CDER.
13-Mar-1995	Acceptance of the request for designation (dated March 13, 1995)
24-Mar-1995	Request for an end of Phase II meeting
4-Apr-1995	EOP II meeting Briefing Package.
28-Apr-1995	Information amendment
3-May-1995	Annual report
9-May-1995	Response to request for status of requested CMC meeting with device and Pilot Drug reviewers.
12-May-1995	Regarding request for designation of CDER as the agency with primary jurisdiction for the pre-market review and regulation of the product.
22-May-1995	Date and time for CMC meeting with Pilot and CDRH set for June 27, 1995.

Date of Contact	Summary of Contact
2-Jun-1995	Five draft pivotal protocols submitted for FDA review and comment.
9-Jun-1995	Inquiry regarding review status of five Phase III protocols (sent June 2, 1995); FDA will fax comments by June 15, 1995.
14-Jun-1995	Comments regarding submission dated April 28, 1994
13-Jul-1995	Draft meeting notes from the FDA/Janssen/ALZA meeting held June 20, 1995 to discuss CMC issues.
1-Aug-1995	Response FDA comments on five pivotal protocols (fax dated June 14, 1995).
14-Aug-1995 to 15-Aug-1995	Teleconference on August 14, 1995 per ALZA request to discuss clarification of written comment concerning C-95-019.
17-Aug-1995	Protocol amendment
28-Aug-1995	Excerpted information from the summary basis of approval for LAAM and the MRO's overview of the "usage" study which is required for ETS fentanyl.
1-Sep-1995	Final meeting minutes from the June 27, 1995 meeting with Pilot Drug and CDRH representatives to discuss CMC issues.
1-Sep-1995	Draft meeting notes from June 27, 1995 CMC meeting have been reviewed without comment from FDA. Request for information
21-Sep-1995	Response to call from FDA regarding final minutes from the June 27, 1995 meeting. Request for information requested at the meeting. ALZA response.
21-Sep-1995	Draft qualification plan in follow-up to the June 27, 1995 meeting with ALZA/Janssen/FDA.
29-Sep-1995	Response to questions from Dr. Lee about the draft Qualification Plan (dated September 21, 1995) asking about electrical current density and dermal responses after administration of ETS (fentanyl).
19-Oct-1995	Request for late November or early December End of Phase II meeting.
27-Oct-1995	Protocol amendment - new protocol C-95-039; information amendment - CMC.
8-Nov-1995	Confirmed date of November 28, 1995 for End of Phase II meeting.
13-Nov-1995	Pre-meeting package for November 28, 1995 End of Phase II meeting.
17-Nov-1995	Protocol amendment - new protocol C-95-032, amendment to C-95-019; information amendment - CMC.
7-Dec-1995	Request for clarification of response to ALZA's proposed ETS placebo design at End of Phase II meeting.
21-Dec-1995	Response to ALZA's December 20, 1995 phone request for information on the closed session of the Advisory Committee.
22-Dec-1995	Meeting minutes from End of Phase II meeting held on November 28, 1995.
16-Jan-1996	Inquiry about status of the End of Phase II meeting minutes (sent December 22, 1995) and date for closed session of Life Support and Anesthetics Advisory Committee.
15-Feb-1996	Confirm April 30, 1996 Advisory Committee meeting and see if there was a final agenda for allotted time. Inquiry about status of draft EOP2 meeting minutes (sent December 22, 1995). Re-confirmed acceptability of C-95-023.

Date of Contact	Summary of Contact
8-Feb-1996	Preclinical and clinical topical safety data related to inquiry from June 27, 1995 meeting.
11-Mar-1996	Agenda for April 30, 1996 closed session of Anesthetics and Life Support Advisory Committee meeting.
14-Mar-1996	Inquiring if the proposed plan not to perform ex-US pivotal trials under the IND would create any problems at FDA in terms of the interactive IND. FDA request for outline labeling. ALZA faxed response.
14-Mar-1996	Copy of the abbreviated draft labeling, provided per FDA request.
18-Mar-1996	FDA issues for April 30, 1996 closed session of Anesthetics and Life Support Advisory Committee meeting.
28-Mar-1996	Draft package for April 30, 1996 closed session of Anesthetics and Life Support Advisory Committee meeting.
5-Apr-1996	Final package for April 30, 1996 closed session of Anesthetics and Life Support Advisory Committee meeting. Same as March 28, 1996 package to Dr. Burke.
16-Apr-1996 to 17 Apr, 1996	Corrected FDA sheets for Advisory Committee. ALZA faxed response of corrections and agenda suggestions. ALZA call to discuss meeting logistics.
17-Apr-1996	Draft agenda for April 30, 1996 closed session Advisory Committee meeting with ALZA/Janssen/FDA per phone request.
3-Jun-1996	Comments from the April 30, 1996 Advisory Committee Meeting.
7-May-1996	Protocol amendment - new protocol C-96-020; information amendment - CMC.
14-May-1996	Annual report covering the period of February 27, 1995 to February 26, 1996.
10-May-1996	Minutes from April 30, 1996 Closed Advisory Committee Meeting with Division of Anesthetics, Critical Care, and Addiction Drug Products.
20-May-1996	Protocol amendment - new protocol C-96-007; information amendment - CMC.
3-Jul-1996	Protocol amendment - new protocol C-96-029; CMC update; new investigator
3-Jul-1996	Protocol amendment - change in protocol C-96-020 (reference SN022, dated May 7, 1996).
9-Jul-1996	Faxed info for teleconference regarding definition of clinically relevant respiratory depression in trials. FDA would like to base definition on respiratory rate and sedation only.
7-Aug-1996 to 8-Aug-1996	August 7, 1996 phone call indicating FDA would like a teleconference to discuss some issues on the clinical program. ALZA faxed response dated August 8, 1996.
16-Aug-1996	Protocol amendment - new protocols C-96-006 and C-96-009; CMC update.
22-Aug-1996	Teleconference to discuss FDA comments (FDA fax dated August 8, 1996) on Phase I protocols for JAN-2, and to discuss specific issues in relation to JAN-1 (ALZA fax dated August 8, 1996).
11-Sep-1996	Response to device questions raised at the April 30, 1996 Life Support and Anesthetics Advisory Committee.
17-Sep-1996	Protocol amendment - change in protocol C-96-006.

Date of Contact	Summary of Contact
24-Sep-1996	Protocol amendment - change in protocol C-96-009.
29-Sep-1996	Pharmacokinetics reviewer comments on skin tolerance protocol C-96-029 (submitted in SN025, dated July 3, 1996).
3-Oct-1996	Teleconference to discuss a question on recent amendment to protocol C-96-006. Comments faxed after teleconference concerning study C-96-009.
15-Oct-1996	Response to FDA comments (fax dated September 29, 1996) on protocol C-96-029-02 (SN25, dated July 3, 1996) regarding calculation of amount of fentanyl delivered.
25-Oct-1996	Response to FDA comments faxed on October 3, 1996 regarding Phase I protocol C-96-009 (SN027, dated August 16, 1996).
20-Nov-1996	Position paper regarding difficulty in distinguishing topical effects related to electrical current versus chemical effects related to the delivery of fentanyl from E-TRANS (fentanyl) systems.
26-Nov-1996	Phase III randomized controlled studies; design and statistical analysis features submitted for FDA comment.
2-Dec-1996	Pharmacokinetic comments from FDA regarding study C-96-009 submitted in SN027 (dated August 19, 1996).
27-Dec-1996	FDA comments regarding the definition of "clinically relevant respiratory depression" in protocols C-97-058-02, C-94-059-02, and C-95-016-02.
6-Jan-1997	Protocol amendment - new protocol C-95-016; CMC update.
6-Jan-1997	Minutes of conference call held between Division of Anesthetic, Critical Care and Addiction Drug Products/ALZA/Janssen.
9-Jan-1997	Request for clinical studies filed to INDs 41,574 and 50,284. ALZA request for clarification of FDA request dated January 2, 1997
17-Jan-1997	Information amendment - clinical with respect to study C-95-016
17-Jan-1997 to 21-Jan-1997	January 17, 1997 request for clarification of FDA phone request dated January 9, 1997. January 21, 1997 FDA phone response.
23-Jan-1997	Response to request for clarification on which clinical protocols were filed to IND 41,574 and IND 50,284 and request for clinical development plans for both projects.
31-Jan-1997	Draft risk analysis standard operating procedure and interim risk analysis.
10-Feb-1997	Proposed finished product specification and rationale documentation; follow-up meeting request.
19-Feb-1997	General correspondence - Submitting 3 Phase III protocols utilizing a reduced on-demand dosage for comment.
12-Mar-1997	Statistician's comments on Phase III pivotal protocols C-94-057-03, C-94-058-02, C-94-059-02, and C-95-016-02
31-Mar-1997	Medical Officer completed review of the 25 µg Phase III protocols (SN040, dated February 19, 1997). Ruled to be safe to proceed.
3-Apr-1997	Information amendment - toxicology; general correspondence - meeting request.
3-Apr-1997	Response to request for information on INDs 41,574 and 50,284

Date of Contact	Summary of Contact
11-Apr-1997	Request that we assign serial numbers and FDA Form 1571s for the April 3, 1997 submission of CMC material.
14-Apr-1997	Form 1571s to complete April 3, 1997 submission of CMC information
23-Apr-1997	Response to request for copy of ALZA regulatory standard (Code #0007075).
11-Apr-1997	Copy of the transcripts from the Closed session of the April 30, 1996 Anesthetic and Life Support Advisory Committee.
18-Apr-1997	Response to statistical comments on Phase III protocols.
2-May-1997	Request for more detailed information on the primary package container materials, which report to justify CPC lower limit on the final product specification, and to change wording for the CPC specification.
8-May-1997	Response to phone request from FDA regarding CMC information.
8-May-1997	Annual report covering the period of February 27, 1996 to February 26, 1997.
16-May-1997	General correspondence - Phase III protocol C-96-057.
17-May-1997	Forwarding FDA's comments regarding Interim Risk Analysis (SN038, dated January 31, 1997).
17-May-1997	Contact information the new CSO for the project.
30-Jun-1997	Request for meeting on CMC information requirements.
14-Aug-1997	Follow-up to last CMC meeting request (dated June 30, 1997), ALZA ready to submit package, waiting for meeting date.
15-Aug-1997	Background package for meeting on CMC.
29-Aug-1997	Response to Medical Review Officer's comments on interim risk analysis performed.
29-Aug-1997	Protocol amendment - change in protocol for study C-95-016.
9-Sep-1997	FDA internal meeting on CMC package planned for September 10, 1997, postponed due to more work needed. Drug development held up.
29-Sep-1997	Minutes from FDA teleconference dated September 25, 1997 to discuss registration batch plans.
28-Oct-1997	Protocol Amendment - new protocol; C-97-001; CMC update.
7-Nov-1997	Protocol amendment - change to Phase I protocol C-97-001 (FEN-USA-63).
12-Nov-1997	Response to CMC questions received via fax on August 21, 1997 in relation to original IND (SN000), SN039 (dated February 10, 1997), SN041 (dated April 3, 1997), and SN044 (dated May 8, 1997).
24-Nov-1997	Protocol amendment - new protocol FEN-USA-29 (C-94-057), new investigator
5-Dec-1997	Protocol amendment - new protocol FEN-USA-28 (C-94-060), new investigator
5-Dec-1997	Protocol amendment - new protocol FEN-USA-58 (C-96-055), new investigator
5-Dec-1997	Response to Pharmacology questions received via fax on August 21, 1997 from CSO in relation to SN041 (dated April 3, 1997).

Date of Contact	Summary of Contact
15-Dec-1997	Follow-up on request for meeting with CDRH regarding device content of the NDA, timing of pre-NDA meeting, and label utilization study.
18-Dec-1997	Call regarding the IND amendment for PK study C-97-001. No issues with the study, but would like to know the status of the study.
14-Jan-1998	FDA suggested information for pre-NDA package in response to ALZA queries.
14-Jan-1998	Protocol amendment - new protocol C-96-056.
20-Jan-1998	Reviewer wanted to know if C-94-057 was a pivotal study. ALZA responded that it was.
20-Jan-1998	Protocol amendment - new protocol C-94-068.
23-Jan-1998	Follow-up on phone messages regarding pivotal status of study C-94-057 (dated January 20, 1998). Faxed reference to where documents have been filed.
2-Feb-1998	Protocol amendment - new investigator documents for studies FEN-USA-29 and FEN-USA-58.
3-Feb-1998	Protocol amendment - change to Phase I protocol C-94-060.
9-Feb-1998	Protocol amendment - new protocol C-96-057.
27-Feb-1998	Protocol amendment - new investigator documentation for C-96-055.
3-Mar-1998	Protocol amendment - new investigator for study FEN-USA-28 (C-94-060).
9-Mar-1998	Initial IND safety report (Ref. #C000201).
13-Mar-1998	Completed review of SN054 (dated November 25, 1997) and SN056 (dated December 5, 1997); FDA requests and comments.
24-Mar-1998	Voicemail acknowledging receipt of request to meet with CDER and CDRH regarding device documentation proposal for the NDA.
25-Mar-1998	Stating that our formal request for a CDER/CDRH teleconference to discuss our proposal for device content/format of the NDA has been granted.
22-Apr-1998	Response to FDA fax regarding statistical comments on protocol C-94-057 and protocol FEN-USA-58.
29-Apr-1998	Notification of temporary suspension of clinical trials due to non-safety related technical issues.
11-May-1998	Pre-meeting package for intercenter teleconference with CDER and CDRH representatives to discuss the device related aspects of the NDA.
15-May-1998	Verification of receipt of three copies of pre-meeting package; would like additional five copies.
15-May-1998	Response to request for five additional copies of SN069 (dated May 11, 1998).
22-May-1998	Annual report covering the period of February 27, 1997 to February 26, 1998.
12-Jun-1998	Final Clinical Development Plan.
22-Jun-1998	Follow-up to query regarding the status of CDER/CDRH meeting request.
17-Jul-1998	Returned call regarding setting up a CDRH teleconference.

Date of Contact	Summary of Contact
10-Aug-1998	List of Janssen and ALZA attendees at the CDER/CDRH teleconference on August 6, 1998.
28-Aug-1998	Sponsor's minutes from intercenter teleconference with CDER/CDRH representatives to discuss device related aspects of NDA.
28-Aug-1998	Meeting request to discuss previous agreements and communications with the Division in relation to the Clinical Development Plan.
23-Sep-1998	Protocol amendment - change in protocol and new investigator for the Phase I protocol C-94-060.
6-Oct-1998	Response to request for FDA meeting to confirm alignment of previous clinical agreements (request dated August 28, 1998, SN073).
26-Oct-1998	Regarding pending request to confirm previous clinical agreements still hold.
29-Oct-1998	Inquiry about availability of minutes from August 6, 1998 CDER/CDRH/Janssen/ALZA meeting to discuss device documentation for NDA.
10-Nov-1998	Questions for Division for requested E-TRANS meeting per submission dated August 28, 1998 (SN073) and phone contact of October 22, 1998.
16-Nov-1998	Protocol amendment - new investigator for C-94-060.
18-Nov-1998	Background package for pending meeting request to discuss agreements/communications related to clinical development plan.
1-Dec-1998	Informing FDA that ALZA unable to attend clinical meeting in December per IND SN076.
1-Dec-1998	Voicemail requesting written withdrawal of meeting request since ALZA unable to attend a clinical meeting early December.
4-Dec-1998	Follow-up on October 19, 1998 fax regarding availability of minutes from August 6, 1998 intercenter meeting with CDER/CDRH/Janssen/ ALZA.
18-Dec-1998	Pre-meeting request to discuss previous agreements and communication with Division regarding clinical development plan.
11-Jan-1999	Verification that FDA received meeting request dated December 18, 1998 (SN077) for February meeting. Request for 15 desk copies of background package.
18-Jan-1999	Follow-up to phone conversation tentatively setting meeting date of February 18, 1999 to discuss clinical development program.
13-Jan-1999	Acknowledgment of receipt of submission dated December 18, 1998 (SN077). Confirmation of requested clinical development FDA meeting scheduled for February 18, 1999.
20-Jan-1999	Information amendment - CMC update.
20-Jan-1999	Follow-up of inquiries dated October 29, 1998 and December 4, 1998 regarding availability of minutes from August 6, 1998 intercenter CDER/CDRH/Janssen/ALZA meeting.
20-Jan-1999	Desk copies of background package for pending meeting request to discuss previous agreements/communications with Division (SN076 and SN077).

Date of Contact	Summary of Contact
8-Feb-1999	Protocol amendment - new protocol C-94-067.
9-Feb-1999	Proposed agenda for February 18, 1999 meeting.
18-Feb-1999	Minutes from February 18, 1999 FDA meeting to discuss clinical program.
22-Feb-1999	Follow-up on fax dated October 29, 1998 and phone call dated December 4, 1998 regarding official FDA minutes from August 6, 1998 CDER/CDRH/Janssen/ALZA meeting.
23-Feb-1999	Six additional copies of SN079 dated February 8, 1999.
26-Feb-1999	Request to meet with CDER and Division of Biopharmaceutics to discuss proposed finished product specifications.
10-Mar-1999	Information amendment - Pharmacology/Toxicology - final report for TR-97-1561-011 and TR-98-1561-031.
11-Mar-1999	Response to the meeting request filed on February 26, 1999 (SN080).
17-Mar-1999	FDA minutes from February 18, 1999 clinical development meeting.
29-Mar-1999	Background package for meeting with CDER and the Division of Biopharmaceutics on April 28, 1999.
19-Apr-1999	Requested changes to minutes for February 18, 1999 meeting; request for teleconference to discuss changes.
19-Apr-1999	Desk copies of SN083.
23-Apr-1999	1999 IND annual report covering the period of February 27, 1998 to February 26, 1999.
29-Apr-1999	Response to request to have team of FDA chemists come to ALZA to see the PSAL and SFTA.
30-Apr-1999	Minutes from FDA meeting on April 28, 1999, including copies of summary overheads presented and agreed with FDA at close of meeting.
30-Apr-1999	Acknowledgment of receipt of April 19, 1999 correspondence (SN083) requesting meeting to discuss response to Agency's February 18, 1999 meeting minutes.
7-May-1999	Inquiry regarding status of two outstanding items, one for JAN-1 and one for CPC-8.
10-May-1999	Recommendations regarding SN081 dated March 10, 1999.
27-May-1999	FDA minutes from April 28, 1999 JAN-1 Biopharm meeting.
1-Jun-1999	Inquiry regarding status of FDA minutes from August 1998 teleconference (ref. SN072 dated August 28, 1998), FDA reply of CPC-8 response letter of March 5, 1998 (ref. SN019), FDA minutes from April 28, 1999 Biopharm meeting (ref. SN085 dated April 30, 1999).
8-Jun-1999	FDA request for disk containing data related to April 28, 1999 Biopharm meeting.
30-Jun-1999	Response to May 10, 1999 correspondence regarding inclusion of two nonclinical topical safety studies in the Investigator's Brochure.
1-Sep-1999	Response to FDA minutes from April 28, 1999 meeting with Division; submission of requested information related to claimed IVIVC; sponsor's request for written response to questions 4&5 from April 28, 1999 meeting.
22-Nov-1999	Confirmation that key agreements reached in prior CMC FDA

Date of Contact	Summary of Contact
	discussions still valid; sponsor minutes from September 25, 1997 teleconference to discuss registration batch manufacturing and stability plans; request FDA minutes from August 6, 1998 teleconference..
8-Dec-1999	Acknowledgment of receipt of CMC agreements submission sent November 22, 1999 (SN088).
21-Jan-2000	Voicemail in follow-up to message indicating FDA receipt of SN088 (dated November 22, 1999).
24-Feb-2000	Request for FDA review of proposed change to the clinical development plan agreed upon at the ALZA/Janssen/FDA meeting on February 18, 1999.
9-Mar-2000	New supervisory Project Manager for Division
14-Mar-2000	Record of phone communication with Supervisory Project Manager in relation to proposed change to clinical development program.
27-Jun-2000	Information amendment - pharmacology/toxicology final reports for nonclinical studies TR-99-1561-056 and TR-99-1562-057.
6-Jul-2000	IND annual report covering the period of February 27, 1999 to February 26, 2000.
18-Jul-2000	Request for preliminary review of new pharmacokinetic protocol C-2000-026.
24-Aug-2000	Request for FDA response to proposal to submit clinical study synopsis for six terminated studies.
5-Sep-2000	Protocol amendment - new protocol C-94-067.
11-Sep-2000	Protocol amendment - new protocols, new investigators; information amendment - clinical, chemistry and microbiology for studies C-2000-005, C-2000-006, C-2000-007, C-2000-008, and C-2000-009.
19-Sep-2000	Response to ALZA request regarding status of FDA review of proposal to submit study synopsis for six safety and efficacy studies stopped in early 1998.
2-Oct-2000	Confirmation of FDA acceptance of proposal to submit clinical study synopses for six E-TRANS studies in the NDA (SN094 dated August 24, 2000).
5-Oct-2000	Protocol amendment - change in protocol C-94-067-04; new protocol C-2000-006-01; new investigator.
11-Oct-2000	Protocol amendment - new investigators.
13-Oct-2000	Contacts between ALZA and FDA regarding status of C-94-067, ruled okay to proceed.
20-Oct-2000	Pharmacokinetic reviewer recommended to add 90 minute sample post start of first dose in C-2000-026 (SN093 dated July 18, 2000).
30-Oct-2000	Protocol amendment - change in protocol; information amendment - clinical for studies C-2000-026 and C-94-067.
6-Nov-2000	Table outlining the old Phase III study numbers, versus the new ALZA study numbers for the five Phase III protocols submitted to FDA on September 11, 2000 (SN096).
9-Nov-2000	Protocol amendment - new investigators for C-2000-005; C-2000-006; C-2000-007; and C-2000-009.
21-Nov-2000	Pre-NDA meeting request.

Date of Contact	Summary of Contact
22-Nov-2000	Request for a January pre-NDA meeting.
29-Nov-2000	Request for a preliminary review of a new safety and clinical utility protocol (C-2000-030).
6-Dec-2000	Protocol amendment - new investigators for C-2000-005; C-2000-007; and C-2000-009.
7-Dec-2000	Response to meeting request dated November 21, 2000.
13-Dec-2000	Desk copy of previous SN103 (dated November 29, 2000).
15-Dec-2000	Background package for pre-NDA meeting.
15-Dec-2000	desk copies of background package for scheduled pre-NDA meeting and disk of cover letter and questions for FDA (SN105).
21-Dec-2000	Notification of termination of investigator participation in Protocol C-2000-007.
22-Dec-2000	Two comments from Medical Review Officer in relation to protocol C-2000-005.
5-Jan-2001	Protocol amendment - new investigators and revised 1572s for C-2000-005, C-2000-007, and C-2000-009.
5-Jan-2001	Response to Medical Review Officer comments on pediatric safety and efficacy protocol C-2000-005.
10-Jan-2001	Asking when and what serial number of the IND studies C-97-001; C-93-023; and C-94-067 were submitted.
11-Jan-2001	Protocol amendment - change in protocol C-2000-008.
12-Jan-2001	Informing that Anesthetics Division and CDRH reviewer had their internal prep. meeting on January 11, 2001 for our January 18, 2001 pre-NDA meeting and had questions.
16-Jan-2001	Response to FDA request for information - clinical.
20-Jan-2001	Response to request for pharmacokinetic simulations.
1-Feb-2001	Informing that FDA has completed clinical review of SN098 (dated October 5, 2000) and have comments.
6-Feb-2001	Informing that FDA has completed review of SN103 (dated November 29, 2000) and have comments/recommendations.
8-Feb-2001	Protocol amendment - new investigators for C-2000-007 and C-2000-009.
12-Feb-2001	Request for teleconference to discuss FDA's February 12, 2001 fax; request for clarification on intent of FDA's February 1, 2001 letter.
12-Feb-2001	:Follow-up to FDA's call on February 6
22-Feb-2001	Background for planned February 23, 2001 FDA teleconference to discuss February 1, 2001 FDA fax.
22-Feb-2001	Notification of termination of investigator participation in Protocol C-2000-009.
23-Feb-2001	ALZA minutes from February 23, 2001 FDA teleconference and IND table of clinical studies.
23-Feb-2001	Table of completed Phase 2 and Phase 3 studies, annotated to include reference to IND location of relevant safety data and final study reports for the short-stay surgery studies.
26-Feb-2001	Response to information requested at the February 23, 2001 teleconference between ALZA and FDA.

Date of Contact	Summary of Contact
5-Mar-2001	Response to messages from ALZA dated March 2, 2001 and March 5, 2001 regarding timing of receipt of FDA's minutes from January 18, 2001 pre-NDA meeting, and FDA input on the Home Safety protocol.
5-Mar-2001	Acknowledgment of receipt of call regarding IND SN113 (dated February 22, 2001). ALZA phone response to acknowledge voicemail.
7-Mar-2001	Interim safety data from ongoing Phase 3 clinical study of E-TRANS (fentanyl) in short-stay surgical patients.
7-Mar-2001	Request for information who is reviewing the Phase 2 data (C-96-020 and C-95-019) in the context of proposed protocol C-2000-030.
9-Mar-2001	Protocol amendment - new investigators for studies C-2000-005 and C-2000-007.
12-Mar-2001	Requested clinical information related to complete Phase 2 study C-96-020.
12-Mar-2001	Information related to Protocol C-2000-009 requested by FDA
12-Mar-2001	Request for information regarding notification of termination of Dr. Cork from participation in study C-2000-009 (IND SN113).
20-Mar-2001	FDA minutes of January 18, 2001 pre-NDA meeting.
23-Mar-2001	IND annual report covering the period of February 27, 2000 to February 5, 2001.
30-Mar-2001	Information related to protocol C-2000-007
6-Apr-2001	Protocol amendment and information amendment for study C-2000-026.
16-Apr-2001	Type A meeting request.
18-Apr-2001	Acknowledgment of receipt of Type A meeting request (SN122 dated April 16, 2001) and indicating May 4, 2001 at 1pm only possible meeting date/time.
19-Apr-2001	Request for available monitoring reports for two terminated sites
25-Apr-2001	Contact regarding the April 16, 2001 Type A meeting request.
25-Apr-2001	Final question #1 and white paper related to previously submitted Type A meeting request.
2-May-2001	Protocol amendment - new investigators for study C-2000-005.
7-May-2001	Division's response to expanded Home Safety study questions (SN123 dated April 25, 2001).
10-May-2001	(Proposed agenda for May 10, 2001 FDA teleconference to discuss Home Safety Study.
14-May-2001	Protocol amendment - New protocol, new investigators - pediatric PK protocol C-2001-006 (in perioperative setting).
15-May-2001	Notification of the June 6, 2001 Type C FDA meeting (original letter dated May 1, 2001).
21-May-2001	Briefing package submitted for June 6, 2001 Type C FDA meeting. Package included ALZA's response to FDA's minutes of the January 18, 2001 pre-NDA meeting.
30-May-2001	FDA minutes of May 10, 2001 teleconference regarding home safety study (original letter dated May 16, 2001).
4-Jun-2001	Response to voicemail requesting pharmacokinetic data.

Date of Contact	Summary of Contact
6-Jun-2001	Response to request for information pertaining to two clinical investigators who participated in the clinical program.
7-Jun-2001	Copy of overhead discussed with FDA at the close of the June 6, 2001 meeting.
2-Jul-2001	Summary overhead of outcomes/agreements from June 6, 2001 FDA meeting.
3-Jul-2001	Official minutes from June 6, 2001 meeting between ALZA and FDA.
5-Jul-2001	FDA minutes of the June 6, 2001 AP-22 meeting.
10-Aug-2001	Request for FDA review of proposed common name for the E-TRANS (fentanyl) acute system.
13-Aug-2001	Request for FDA review of protocol C-2001-011.
30-Aug-2001	Protocol amendment - new investigators for study C-2000-005.
7-Sep-2001	Protocol amendment - change in protocol for study C-2001-006.
1-Oct-2001	FDA comments on protocol C-2001-011 (submitted in SN131 dated August 13, 2001).
12-Oct-2001	Protocol amendment - New protocol and new investigator for protocol C-2001-009; Information amendment - clinical.
12-Oct-2001	Clinical information amendment submitted reflecting changes to 1572's previously submitted in SN126 with the original protocol C-2001-006.
15-Oct-2001	Regarding items related to the planned e-NDA and plan to fax in a proposal to submit the risk management plan to the NDA at the 6-7 month review period following NDA submission.
26-Oct-2001	Protocol and information amendment for protocol C-2001-011.
7-Jan-2002	Inquiry about status of August 10, 2001 IND submission (SN130), which requested FDA review of proposed generic (common name) for E-TRANS (fentanyl) product.
10-Jan-2002	Submission of protocol amendment - new investigator; information amendment - clinical for studies C-2000-007, C-2000-008, and C-2001-011.
15-Jan-2002	Response to inquiry regarding status of August 10, 2001 IND submission (SN130), which requested FDA review of proposed generic (common name) for the E-TRANS (fentanyl) product.
14-Mar-2002	Submission of protocol amendment - change in protocol C-2001-011.
10-Apr-2002	General correspondence related to IND SN130 - request for review of proposed generic descriptor.
24-Apr-2002	IND annual report covering the period of February 6, 2001 to February 26, 2002.
13-May-2002	Protocol amendment - new investigator and information amendment - clinical for C-2001-011.
14-May-2002	Proposed formats of clinical reports and case report tabulations to be included in the NDA.
8-Aug-2002	Protocol amendment - new protocol; protocol amendment - new investigator.
22-Aug-2002	Protocol amendment - change in protocol.
9-Oct-2002	Informing about the Clinical Trials Data Bank.

Date of Contact	Summary of Contact
28-Apr-2003	Request for a trademark consultation on the proposed Tradename
9-May-2003	Contact pertaining to the Tradename submission
9-May-2003	IND annual report covering the period of February 27, 2002 to February 26, 2003.
30-Jul-2003	Regarding meeting with Toni Nearing (WDC Liaison), Mark Kramer, and Patricia Love at the office of Combination Products on July 30, 2003.
11-Aug-2003	Minutes from teleconference held with the Office of Information Management Staff regarding planned electronic NDA for E-TRANS (fentanyl); outline of e-NDA planned for submission in late September 2003.
17-Dec-2003	Protocol amendment - new protocol CAPSS-319 and new investigator information; information amendment - CMC information for protocol CAPSS-319.
26-Feb-2004	Protocol Amendment - change in protocol CAPSS-319; Information Amendment - Change in contract packager
2-Mar-2004	Protocol Amendment - New Protocol CAPSS-320 and New Investigator Information; Information Amendment - CMC Information for Protocol CAPSS-320
2-Apr-2004	Protocol amendment - change in protocol CAPSS-320.
14-Apr-2004	Protocol Amendment: New Investigators
19-Apr-2004	Annual Report covering the reporting period of February 27, 2003 to February 26, 2004.
14-May-2004	Protocol Amendment: New Investigators
26-May-2004	Protocol Amendment: New Investigators.
14-Jun-2004	Protocol Amendment: New Investigators.
23-Jun-2004	Protocol Amendment: New Investigators.
14-Jul-2004	Protocol Amendment: New Investigators.
21-Jul-2004	Protocol Amendment: New Investigators.
13-Aug-2004	Protocol Amendment: New Investigators.
18-Aug-2004	Protocol Amendment: New Investigators.
14-Sep-2004	Protocol Amendment: New Investigators.
15-Sep-2004	Protocol Amendment: New Investigators.
13-Oct-2004	Protocol Amendment: New Investigators.
13-Oct-2004	Protocol Amendment: New Investigators.
3-Nov-2004	Protocol Amendment: Change in Protocols CAPSS-319 and CAPSS-320
12-Nov-2004	Formal submission containing new investigator documentation for study CAPSS-319. This submission was assembled and sent by our CRO Pharmanet on behalf of ALZA.
12-Nov-2004	Formal submission containing new investigator documentation for study CAPSS-320. This submission was assembled and sent by our CRO Pharmanet on behalf of ALZA.
16-Dec-2004	Protocol Amendment: New Investigators.

Date of Contact	Summary of Contact
16-Dec-2004	Protocol Amendment: New Investigators.
7-Jan-2005	Protocol Amendment: Change in Protocol CAPSS-320.
14-Jan-2005	Protocol Amendment: New Investigators.
11-Feb-2005	Protocol Amendment: New Investigators.
14-Feb-2005	Protocol Amendment: Change in Protocol CAPSS-320.
11-Mar-2005	Protocol Amendment: New Investigators
31-Mar-2005	Annual Report for reporting period 2/27/2004 to 2/26/2005
15-Apr-2005	Protocol Amendment: New Investigators
2-Jun-2005	Protocol Amendment: New Protocol and New Investigator Info; Information Amendment
29-Jun-2005	Protocol Amendment: Change in Protocol C-2004-016 and New Investigator Information
25-Jul-2005	Protocol Amendment: New Investigators
25-Jul-2005	Amendments 3 & 4 of Protocol C-2004-016 (Serial No. 187) was submitted to the Agency on July 25, 2005.
2-Dec-2005	Protocol Amendment: New Investigators
17-Jan-2006	Protocol amendment - new protocol C-2005-028 and new investigator information; information amendment - CMC information for protocol C-2005-028 and supportive nonclinical data.
27-Jan-2006	Protocol amendment
24-Apr-2006	IND Annual Report 2/27/2005 to 2/26/2006

**NDA Activities**

Date	Summary of Contact
27-Oct-2000	Confirmation of NDA number (21-338) and the User Fee ID Number (4054).
12-Mar-2002	Request for a User Fee Identification Number for NDA 21-338 per instructions on FDA Form 3397 (User Fee Cover Sheet).
21-Mar-2002	Response to ALZA's inquiry about setting up encrypted e-mail between ALZA and the Division to facilitate communication during review of the eNDA.
11-Apr-2002	Information on setting up encrypted e-mail between ALZA and the Division of Anesthetics, Critical Care, and Addiction Drug Products in preparation for the AP-22 NDA.
31-Jan-2003	Inquiry about when ALZA plans to submit the NDA.
13-Jun-2003	Return telephone call regarding Dr. McNeil, Medical Reviewer who's been reviewing C-2002-027 in the IND and wondered about the status of the study. Informing of ALZA's plans to submit the e-NDA late September or early October 2003.
3-Jul-2003	DLT test generated by ALZA to confirm logging in process for official tape/submission. Levin forwarded e-mail to Ken Edmunds, electronic submissions coordinator. Teleconference request for July 14, 2003 or July 28, 2003.
9-Jul-2003	Call to inform Compton of Regulatory Operations staff's July 7, 2003 e-mail to Levin to discuss aspects of the planned eNDA in late September or early October 2003.
29-Jul-2003	Teleconference to discuss the AP-22 eNDA test DLT tape submitted to CDER.
28-Aug-2003	User Fee sent by FedEx to the Mellon Client Service Center in Pittsburgh, PA.
23-Sep-2003	FDA advised to submit the DLT NDA tape, along with the originals of signed administrative documents in archival NDA jackets, and provided address for mailing of archival and desk copies.
25-Sep-2003	Submission of original new drug application (NDA) in electronic format.
10-Oct-2003	Regarding NDA filing date. 60 day filing date will be November 21, 2003. Looking to schedule filing meeting week of November 3, 2003.
15-Oct-2003	Acknowledgment of receipt of original NDA dated September 23, 2003. FDA internal filing meeting to take place week of November 23, 2003. Ten-month PDUFA review goal date is July 24, 2004.
6-Nov-2003	Request related to the AP-22 NDA case report forms for clinical studies C-94-057; C-94-058; and C-94-059.
10-Nov-2003	Response to November 6, 2003 phone request from MRO for case report form table of contents for clinical studies C-94-057; C-94-058; and C-94-059.
12-Nov-2003	Amendment - revised case report forms table of contents for clinical studies C-94-057, C-94-058, and C-94-059.

Date	Summary of Contact
13-Nov-2003	Request from statistical reviewer for documentation related to data sets, and if possible, programs used to product efficacy results in reports and analysis.
14-Nov-2003	Amendment - CD-ROM containing combined sets of safety narratives organized by clinical/pharmacokinetics study and patient ID number.
14-Nov-2003	Asked if the request received via phone on November 13, 2003 was a fileability issue request.
25-Nov-2003	Verification that the AP-22 NDA has been officially filed as of November 23, 2003.
3-Dec-2003	Amendment - CD-ROM containing documentation related to data sets and programs used to produce efficacy results in reports and analysis.
5-Dec-2003	NDA filing review completed (submissions dated September 24, 2003; November 12, 2003; and November 14, 2003). No potential filing review issues noted to date. No major deficiencies noted thus far into the preliminary evaluation of the application.
17-Dec-2003	Regarding appropriate FDA contacts to discuss proposal for handling commercial product complaints.
2003-Dec-31 to 2004-Jan-02	Request from a reviewing chemist to send placebo systems and any instructional materials needed to operate the system. ALZA response.
6-Jan-2004	Return call regarding possible meeting with FDA to discuss issues related to CDER/CDRH compliance grey zones eg complaints reporting, AE reporting, and jurisdictional issues for PAI.
6-Jan-2004	Message requesting information on the manufacturing flow and ALZA response.
20-Jan-2004	4-month safety update report.
21-Jan-2004	Requested demonstrator systems of E-TRANS (fentanyl HCl) system.
23-Jan-2004	Question regarding ALZA's proposed risk management plan and ALZA response.
28-Jan-2004	Confirmation that AP-22 will not go to Advisory Committee, unless/until we decide to pursue an outpatient indication. Inquiry regarding when we will submit a more detailed risk management plan.
2-Feb-2004	Response to call from FDA dated January 28, 2004. FDA inquiry concerning timing of a more detailed risk management plan. being submitted to the NDA.
12-Feb-2004	Request for information regarding clinical section of the original NDA (dated September 23, 2003).
12-Mar-2004	Response to FDA's February 12, 2004 request for information
15-Mar-2004	Request for FDA response regarding proposals for post-marketing safety reporting, product complaints investigation/reporting, and pre-approval inspectional jurisdiction.
15-Mar-2004	Request for information regarding pharmacokinetic data sets for C-93-023-00 and C-2001-006-02
15-Mar-2004	Response to February 12, 2004 Information Request Letter.

Date	Summary of Contact
21-Mar-2004	Response to FDA request for information
22-Mar-2004	Response to FDA's March 15, 2004 request for information.
25-Mar-2004	Request for review of proposed trade name IONSYS and generic product descriptor.
26-Mar-2004	Response to Project Manager's request for pharmacokinetic data (request dated March 15, 2004).
2-Apr-2004	Risk management proposal. Supercedes the risk management outline submitted with original eNDA.
8-Apr-2004	Requested Copy of Volume 1 of Electronic NDA 21-338
12-Apr-2004	Request for information regarding original NDA filing (dated September 23, 2003). CDRH has reviewed the device manufacturing section and requests additional information.
16-Apr-2004	Statistician would like to know if ALZA is planning to update the stability data and if so, when.
16-Apr-2004	NDA Amendment - Update of CMC Information; Revised Labeling.
16-Apr-2004	Copy of NDA Amendment dated April 16, 2004 was sent to FDA Field Office.
19-Apr-2004	Response to FDA question from statistician re: stability data.
19-Apr-2004	Confirmation of receipt of information re: stability data sent on April 16, 2004.
22-Apr-2004	Copy of Clinical Information Request Letter.
22-Apr-2004 & 28-Apr-2004	Copy of CMC Information Request Letter.
30-Apr-2004	NDA Amendment - Response to Information Request Letter.
30-Apr-2004	Notification to District Office of NDA Amendment.
30-Apr-2004	Response to Second Clinical Request for Information Letter for IONSYS
13-May-2004	Response to April 22, 2004 CMC Information Request Letter.
13-May-2004	Copy of cover letter for response to CMC Information Request letter sent to the Alameda District Office.
25-May-2004	Response to Request for Information.
25-May-2004	Request for additional information following FDA monthly review meeting. FDA proposes a telecon for an information exchange (response to questions).
27-May-2004	Call to confirm June 15 telecon. Also, verification that the FDA wants both button pressing data and gel stability data from 9-mo.
3-Jun-2004	Confirmation of receipt of CMC/ device questions and notification that some of the items have been compiled and will be sent on 6/4. Also, notification that the technical group will be working to answer the remaining questions prior to the scheduled 6/15 telecon.
3-Jun-2004	Copy of CMC Information Request Letter.
4-Jun-2004	Requested Updated Stability Report; Response to Question Raised During Pre-approval Inspection.

Date	Summary of Contact
9-Jun-2004	Follow-up on questions re: proposed tradename and post marketing complaints/ safety reporting. Also, follow-up re: ALZA's request for clarification on question #7 of the most recent Information Request Letter.
9-Jun-2004	Request for FDA-input for the planned teleconference on June 15 following the internal FDA prep. Meeting.
11-Jun-2004	Response to Information Request Letter dated May 28, 2004.
14-Jun-2004	Copies of cover letters for 6/4/04 Response to Request for 9-month Corrective Action Lot Stability Update and Response to Question Raised during Pre-approval Inspection, and 6/11/04 Response to May 28, 2004 Information Request Letter.
14-Jun-2004	List of discussion topics for 6/15/04 teleconference.
16-Jun-2004	Copy of list of J&J attendees from the 6/15/04 teleconference.
21-Jun-2004	Inquiry re: CMC Information Request Letter to be forthcoming from Agency
24-Jun-2004	Return call re: inquiry about the status of the CMC IRL.
29-Jun-2004 to 30-Jun-2004	Response to points raised during teleconferences held on 6/15/04 and 6/30/04.
1-Jul-2004	Request for confirmation of receipt of response to points raised during 6/30 teleconference. Also, inquiry as to whether the primary review on the NDA are complete or if further questions might be forthcoming.
1-Jul-2004	Responses to Points Raised in the June 15, 2004 and June 30, 2004 Teleconferences.
7-Jul-2004	Telecon to discuss reconciliation of the stability data and analysis from submissions dated 6/4/04 and 6/11/04.
7-Jul-2004	Request for clarification on a point re: adhesion discussed in the 7/7 teleconference.
9-Jul-2004	Copy of FDA minutes of the IONSYS CMC teleconference held on 7/7/04.
9-Jul-2004	Teleconference and follow-up e-mail re: FDA question regarding the structure and chemical formula for R004380.
13-Jul-2004	Responses to Request for Methods Validation Document Package.
16-Jul-2004	Copies of cover letters for two electronic amendments for CMC submissions (18.1 and 19.1) forwarded to the FDA Alameda District Office.
17-Jul-2004	Response to CMC Memo dated 7/9/04; Formal Submission of Previously Communicated Nonclinical Response; Formal Submission of Revised Physician Insert.
23-Jul-2004	Copy of NDA action letter (approvable) and CDRH Discipline Review letter received via e-mail.
23-Jul-2004	Hardcopy of NDA action letter (approvable) received from the Agency via regular mail. The CDRH Discipline Review letter was NOT received via hardcopy, but by e-mail only.
23-Jul-2004	Copy of NDA action letter (approvable) and CDRH Discipline Review letter received from the Agency via e-mail.
23-Jul-2004	Hardcopy of CDRH Discipline Review letter.

Date	Summary of Contact
28-Jul-2004 thru 29-Jul-2004	Request for clarification from the Agency regarding expectations on response to the CDRH Discipline Review letter and the approvable letter. Also requested a teleconference with Dr. Rappaport.
29-Jul-2004	Returned call re: request for a telecon w/Dr. Rappaport. Jani stated that the response to the CDRH letter should be part of the complete response, but that issues raised in the CDRH letter were not approvability issues.
30-Jul-2004	Initial response to action letter as well as a request for a face-to-face meeting to clarify some of the points in the letter.
30-Jul-2004	Receipt of Action Letter and Intent to Amend the NDA with a Complete Response.
6-Aug-2004	Call from Compton to offer the date of September 10 for the AP-22 meeting to clarify issues in the NDA action letter.
11-Aug-2004	Confirmation of Type A meeting with the Agency on September 10, 2004.
11-Aug-2004	Official letter from FDA granting Type A meeting to discuss approvable letter and CDRH letter.
18-Aug-2004	Copy of letter containing the Agency's comments on the proposed Risk Management Plan.
24-Aug-2004	Sponsor's questions for September 10, 2004 meeting w/FDA to discuss the approvable letter for NDA 21-338.
10-Sep-2004	Copy of slides presented by the FDA at the September 10 Type A Post-Action Meeting.
21-Sep-2004	Questions re: when we can expect to receive the minutes of the 9/10 meeting, as well as inquiry as to whether it would be useful to send a video on how E-TRANS works.
27-Sep-2004	Call re: desire to get an early review of the draft CDRH response.
30-Sep-2004	Questions re NDA 21-338.
7-Oct-2004	FDA review of IONSYS name.
8-Oct-2004	FDA minutes of the 9/10/04 IONSYS meeting.
29-Oct-2004	Type A Meeting Request: Clinical; Comments/Request to Correct Items in FDA's Minutes of September 10, 2004 Meeting.
29-Oct-2004	Type A meeting request: Clinical; Comments/Request to correct items in FDA minutes of Sept 10, 2004 meeting
15-Nov-2004	Briefing Package for AP-22 Type A FDA Meeting (clinical) scheduled for December 2, 2004
15-Nov-2004	Notification briefing package for Dec 2 Type A meeting was Fed Ex'd
17-Nov-2004	Confirmation letter for Type A meeting request: clinical for IONSYS on December 2, 2004
17-Nov-2004	Cover letter and briefing package/question for FDA for Dec 2, 2004 meeting
17-Nov-2004	Two Videos: Clinical Companion Video: Information for Healthcare Professionals and Clinical Companion: Information for Patients.
23-Nov-2004	Outcome of FDA's pre-meeting planned for December 2, 2004 Type A meeting.

Date	Summary of Contact
9-Dec-2004	Agency Responses (Final) to sponsor's questions in meeting package for the IONSYS (Fentanyl HCl) product.
20-Dec-2004	Type B Meeting Request: CMC/CDRH Issues
4 to 5 Jan 2005	E-mail regarding potential CMC/CDRH meeting date
6 to 7 Jan 2005	Confirming Feb.10, 2005 CMC/CDRH meeting with the agency for NDA 21-338
6 to 7 Jan 2005	Confirming of acceptance of Feb.10, 2005 CMC/CDRH meeting with the agency for NDA 21-338
13-Jan-2005	briefing package/questions for 2/10/05 FDA meeting
8-Feb-2005	FDA responses to questions posed for 2/10/05 CMC/CDRH meeting.
9-Feb-2005	FDA will pass on ALZA's clinical questions re: resubmission to medical officer
10-Feb-2005	ALZA's summary minutes of the Feb 10, 205 CMC/CDRH FDA teleconference.
25-Feb-2005	Clinical questions for the medical reviewer team leader at the FDA
1-Mar-2005	Formal submission of an e-mail sent to Kim Compton by ALZA on 2/25/05 containing clinical questions for the medical reviewer and/or medical team leader at the FDA
7-Mar-2005	FDA's minutes of the Feb. 10 teleconference IONSYS CDER/CDRH (CMC issues and draft response to CDRH Discipline review letter)
7-Mar-2005	E-TRANS Clinical questions
11-Mar-2005	sent response to FDA for E-TRANS fentanyl re: FDA questions on EU Trial Report FEN-PPA-401
23-Mar-2005	Follow up to Question 1 (adequacy of CDRH response)
31-Mar-2005	NDA 21-338 E-trans Fentanyl System - Device Issues
8-Apr-2005	Copy of planned TOC for the NDA resubmission was provided to the Agency for review.
8-Apr-2005	Agency confirmed its agreement on the Company's proposal to submit an abbreviated ICH study report for the EU trial FEN-PPA-401 in the NDA submission
22-Apr-2005	Type C Face-to-Face Meeting Request and Briefing Package: response to Office of Drug Safety Comments on the Original RiskMAP and revised draft risk minimization action plan.
6-May-2005	Informing that the Division will issue a letter to deny April 22, 2005 request for meeting to discuss the RiskMAP. The division felt the questions posed in the meeting request package could be addressed in written form.
9-May-2005	Regarding the revised RiskMAP and ODS response that was submitted as part of the meeting request (dated April 22, 2005).
10-May-2005	Request for additional copies of the RiskMAP meeting package. Also included are responses to Kim's inquiry regarding the status of two items.
12-May-2005	Copy of ALZA's minutes of the April 1, 2005 teleconference submitted to the Agency.
12-May-2005	Sponsor's minutes of the April 1, 2005 teleconference with the Agency.

Date	Summary of Contact
16-May-2005	Letter advising that the Agency will provide written comments to questions in the proposed meeting request in lieu of a meeting.
27-May-2005	FDA's minutes of the April 1, 2005 Division/CDRH/OC teleconference. Purpose of the meeting was to discuss subject pertaining to the IONSYS NDA resubmission.
23-Jun-2005	Discussion of PK, AEs, and risk management plan
23-Jun-2005	Continuation of discussion regarding clinical questions for the medical reviewer [cf. RACRs dated 25-Feb-2005 and 08-Apr-2005]
20-Jul-2005	voicemail with a question about where to find a referenced risk management analysis (D220005).
29-07-2005	RMP letter response to meeting request
1-Aug-2005	Call to thank the FDA for the responses to our questions on the revised RiskMap.
8-Sep-2005	Call to discuss SPL and whether this is a requirement that would affect the IONSYS resubmission or is applicable only to new registration applications made after Oct. 31, 2005.
21-Sep-2005	Follow-up to the 9/8/05 conversation re: SPL requirement
16-Nov-2005	Courtesy message informing Kim Compton of ALZA's plan for submitting the resubmission/complete response on 11/21/05 and the content and format in which the submission will be sent to the July 2004 approvable letter.
18-Nov-2005	confirmed FDA mailing address & Agency has 14 days to determine if response is complete.
21-Nov-2005	Submission of Complete Response
22-Nov-2005	Request by the Agency to submit requested information on the specification no later than March 15, 2006 to facilitate the review process.
29-Nov-2005	Confirmation that the Agency received ALZA's response to the July 23, 2004 Action Letter. The Agency will decide by December 6, 2005 whether it is a complete response and thus restarts the clock.
1-Dec-2005	Follow-up to FDA's inquiry about submission of information related to specification.
6-Dec-2005 to 7-Dec-2005	Notification the NDA resubmission submitted on 11/11/05 is a complete response to FDA's 7/23/05 approvable letter.
9-Dec-2005	Official letter from the FDA re: the IONSYS NDA resubmission. The Agency considers the resubmission as a complete, Class 2 response to the July 23, 2004 action letter and the PDUFA user fee goal date is May 22, 2006.
13-Dec-2005	Voicemail regarding analytical lab
13-Dec-2005	Voicemail regarding one of J&J sites
6-Jan-2006	Withdrawal of Analytical Testing Laboratory.
17-Jan-2006	E-mail to inform FDA project manager of the IONSYS EMEA communication regarding the delay in EU launch due to a recently identified issue with the commercial manufacturing process for IONSYS.

Date	Summary of Contact
2-Feb-2006	Request from the Agency for samples (placebo) of the IONSYS system.
10-Feb-2006	Samples of IONSYS System (demo units without gels) sent to Agency for review.
14-Feb-2006	FDA rec'd the IONSYS systems (20 sample units) ALZA submitted 2/10/06
23-Feb-2006 to 24-Feb-2006	Request from the Agency for a brief teleconference for February 27, 2006 to clarify a couple of items on the proposed RMP for IONSYS.
27-Feb-2006	Telecon at FDA's request to discuss some items related to revised Risk Map (submitted April 2005) and NDA resubmission response to FDA's July 29, 2005 letter with comments on the revised Risk Map.
10-Mar-2006	CMC question for the Agency regarding the difference in POC and CAL lots. Heads up that comments/requests from CDRH will be coming soon.
14-Mar-2006	NDA amendment containing revised specs for Impurity A, B and FC1003
15-Mar-2006	Field copy of NDA amendment containing revised specs for Impurity A, B and FC1003 sent to District Office
21-Mar-2006	Submitted the revised IONSYS RiskMAP (March 2006 edition)
22-Mar-2006	Questions from the Center of Devices and Radiological Health (CDRH)
24-Mar-2006	FDA teleconference scheduled for March 30, 2006
27-Mar-2006 to 28-Mar-2006	List of FDA invited attendees for the 3/30/06 teleconference to discuss items outlined in the 3/22/06 CDRH letter. Also, FDA comments on the proposed patients instructions for use for IONSYS.
29-Mar-2006	List of ALZA/J&J attendees and questions for the Agency for the March 30, 2006 teleconference to discuss comments from the March 22, 2006 CDRH letter.
30-Mar-2006	Agency is not planning to issue minutes for the March 30, 2006 teleconference. Company targeting to submit a bulk of the responses to the March 22, 2006 CDRH letter to the Agency by April 7th and the remaining responses by April 14th.
4-Apr-2006	Follow-up action item from telecon w/ FDA re: educational materials and proposed revisions to FDA's version of PI labeling
4-Apr-2006	Telecon at FDA's request regarding Risk Map/review issues
5-Apr-2006	Response to request for information
6-Apr-2006	Response to 3/22/06 information request letter
12-Apr-2006	Educational materials sent electronically as a follow-up to 4/11/06 email request
13-Apr-2006	Response to proposed educational material request
13-Apr-2006	Response to 3/22/06 information request letter (remaining questions)
19-Apr-2006	Follow-up to the April 3, 2006 telecon: email the EU PI and PPI and submit in writing where ALZA stands on the setting for IONSYS.

Date	Summary of Contact
19-Apr-2006	ALZA's response to Ms. Compton's email 4/18/06 with a request to send European PI (SmPC) and PPI for IONSYS.
20-Apr-2006	Request from FDA (CMC team) to update the drug product specifications table to include the proposed test and acceptance criteria for "Dose Charge."
21-Apr-2006	ALZA's response to the issue at the April, 3 2006 FDA teleconference, regarding the appropriate setting for use of IONSYS.
21-Apr-2006	Re: IONSYS and Duragesic, tcon and packaging consideration.
24-Apr-2006	Response to additional requests received via e-mail from FDA on April 18, 2006. (vn 38)
24-Apr-2006	List of participants in ALZA/FDA teleconference re: IONSYS NDA.
24-Apr-2006	Response to the April 20, 2006 request from CMC reviewer to add dose charge to the drug product specification (response to Question 4 in the July 9, 2004 amendment).
24-Apr-2006	Tcon to discuss disposal and packaging label issue
27-Apr-2006	Proposed revised label text re: red tab on IONSYS
30-Apr-2006	Clinical response in follow up to the April 24, 2006 teleconference with FDA.
1-May-2006	Response to two information requests from the April 24, 2006 telecon regarding: 1) pulling on the red tab of the IONSYS system and 2) clarification supporting nurses' understanding of the appropriate use of IONSYS.
1-May-2006	Acknowledgment of receipt of ALZA's clinical response, in follow up to the April 24, 2006 telecon with FDA.
2-May-2006	CMC request and to send validation pkg for SFTA test method
5-May-2006	Questions from FDA re: labeling items
10-May-2006	Response to FDA Request for SFTA Method Validation Packag
10-May-2006	Response to FDA 5/5/05 letter re: labeling items
11-May-2006	FDA acknowledgement re: Patient Bedside Sheet w/ no action needed from ALZA
11-May-2006	PT Bedside Sheet - one small change
11-May-2006	Telephone call pertaining to IONSYS labeling
11-May-2006	Response to May 5, 2006 FDA request
11-May-2006	Provided revised drug product specs to FDA
12-May-2006	FDA's comments on the IONSYS labeling (PI).
12-May-2006	Letter from the FDA containing Office of Drug Safety/Controlled Substances Staff (ODS/CSS) comments on the IONSYS RiskMAP.
15-May-2006	Comments from FDA requesting revisions to the carton and container labels.
16-May-2006	Physician's labeling and Word version of the patient labeling for IONSYS sent via e-mail to FDA.

Date	Summary of Contact
17-May-2006	Response to May 12, 2006 and May 16, 2006 FDA request for IONSYS labeling (PI and patient bedside information sheet).
17-May-2006	FDA Project Manager confirmed receipt of the Physician's labeling and Word version of the patient labeling that was sent on a CD via FedEx to FDA.
18-May-2006	Modification to section of the PI, as discussed during the May 18, 2006 telecon w/FDA.
18-May-2006	IONSYS Physicial label (PI) from the FDA.
18-May-2006	FDA Project Manager confirmed receipt of the IONSYS May 18, 2006 submission.
18-May-2006	Revised color mock up of the IONSYS system print. "Patient-activated" has been deleted and replaced with "40 mcg/activation" per FDA request.
18-May-2006	Response to FDA Discipline Review letter from ODS/CSS dated May 12, 2006 regarding the IONSYS RiskMAP.
18-May-2006	Response to FDA Discipline Review Letter dated May 12, 2006 on the IONSYS RiskMAP.
19-May-2006	Submission related to the Proposed Draft Label (PI) for IONSYS. The cover letter is dated May 19, 2006 and the electronic version of this submission was sent via secure e-mail to FDA on May 19, 2006.
19-May-2006	Response to FDA inquiry re: exclusivity. In the cover letter of the original NDA, ALZA requested 3 years exclusivity due to the fact that we conducted significant clinical trials for IONSYS (per CFR 21 314.108).
19-May-2006	Submission of the subanalysis for the Nurse Ease of Care (EOC). Information was sent on May 18, 2006 via secure e-mail to FDA.
19-May-2006	Confirmation from FDA regarding acknowledgement of minor typo/correction to p.18 of the PI.
19-May-2006	ALZA's final draft of the IONSYS label submitted to the Agency.
19-May-2006	Followup on the subject of agreement with the Agency on the Risk Management Plan. Request to come to an agreement on a reasonable timeframe in which agreement on the Risk Management Plan would be obtained with the Agency.
19-May-2006	Dialogue between the Sponsor and the Agency regarding the timeframe related to agreement on the Risk Management Plan for IONSYS with the Agency.
21-May-2006	Discussion related to Risk Management Plan (RiskMAP).
22-May-2006	Approval letter for IONSYS